City Therapeutics raises $200 million in IPO, becoming 26th biotech listing of 2026
read at Endpoints ↗DealPositive
City Therapeutics announced that it has completed a $200 million initial public offering, making it the 26th biotech to go public in 2026.
The company, based in Kendall Square, will begin trading on Friday morning, adding to a recent surge in biotech listings.
City Therapeutics says the proceeds will support its effort to develop an "Alnylam 2.0" platform in the RNA interference (RNAi) space.
The IPO reflects continued investor interest in emerging RNAi technologies despite broader market fluctuations.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field”
read at Endpoints ↗90 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that